作者: Martin Rohrer
DOI: 10.1007/978-3-540-77861-5_1
关键词:
摘要: Twenty years ago, the first MRI contrast medium (MRI-CM) was introduced to market: in 1988, Gd-DTPA (Magnevist®, Bayer Schering Pharma AG, Berlin, Germany) received market approval for clinical use United States, Europe and Japan. In follow, application of MRI-CM became a widely established, powerful tool improved diagnosis approximately 30% all examinations worldwide [1, 2, 3, 4, 5].